Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Opdam FL"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Lancet. 3/12/2011, Vol. 377 Issue 9769, p900-901. 3p.
Publikováno v:
Journal of Clinical Oncology; 2/1/2012, Vol. 30 Issue 4, p464-464, 1p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wilding B; Boehringer Ingelheim, Vienna, Austria., Woelflingseder L; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Baum A; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Chylinski K; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Vainorius G; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gibson N; Boehringer Ingelheim (Germany), Germany., Waizenegger IC; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Gerlach D; Boehringer Ingelheim (Austria), Vienna, Austria., Augsten M; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Spreitzer F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Shirai Y; National Cancer Center Research Institute, Tokyo, Tokyo, Japan., Ikegami M; National Cancer Center Research Institute, Tokyo, Tokyo, Japan., Tilandyova S; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Scharn D; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Pearson MA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Popow J; Boehringer Ingelheim (Austria), Vienna, Austria., Obenauf AC; Research Institute of Molecular Pathology, Vienna, Austria., Yamamoto N; National Cancer Center Hospital, Tokyo, Japan., Kondo S; National Cancer Center Hospital, Tokyo, Japan., Opdam FL; Netherlands Cancer Institute, Amsterdam, Netherlands., Bruining A; Netherlands Cancer Institute, Amsterdam, Netherlands., Kohsaka S; National Cancer Center Research Institute, Tokyo, Tokyo, Japan., Kraut N; Discovery Research, Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Heymach JV; The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Solca F; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria., Neumuller RA; Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 Sep 09. Date of Electronic Publication: 2024 Sep 09.
Autor:
Embaby A; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Huijberts SCFA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Internal Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Leite de Oliveira R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Human Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; CEMM, Oncode Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sanders J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Steenis C; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kluin RJC; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lieftink C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Smith CG; NeoGenomics, Babraham Research Park, Cambridge, United Kingdom., Blank CU; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Thienen JV; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Haanen JBAG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Steeghs N; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Beijnen JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Schellens JHM; Faculty of Science, Utrecht University, Utrecht, the Netherlands., Wilgenhof S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Aug 01; Vol. 30 (15), pp. 3157-3166.
Autor:
van der Heijden LT; Department of Pharmacology and Pharmacy, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands. l.vd.heijden@nki.nl.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands. l.vd.heijden@nki.nl.; Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, The Netherlands. l.vd.heijden@nki.nl., Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacology and Pharmacy, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmaco-Epidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Huitema ADR; Department of Pharmacology and Pharmacy, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Pharmacology, Princess Maxima Center, Utrecht, The Netherlands.
Publikováno v:
European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2024 Jul; Vol. 49 (4), pp. 407-418. Date of Electronic Publication: 2024 Apr 30.
Autor:
van der Heijden LT; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Ribbers CA; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Vermunt MAC; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Pluim D; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Acda M; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Tibben M; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands., Douma JAJ; Department of Clinical Pharmacology, Division of Medical Oncology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, The Netherlands.; Department of Internal Medicine, Medisch Centrum Leeuwarden, Leeuwarden, The Netherlands., Naipal K; Department of Clinical Pharmacology, Division of Medical Oncology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, The Netherlands., Bergman AM; Department of Clinical Pharmacology, Division of Medical Oncology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, The Netherlands.; Department of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmaco-epidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht Utrecht University, Utrecht, The Netherlands.; Department of Pharmacology, Princess Maxima Center, Utrecht, The Netherlands., Opdam FL; Department of Clinical Pharmacology, Division of Medical Oncology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute, The Netherlands.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2024 Feb; Vol. 64 (2), pp. 155-163. Date of Electronic Publication: 2023 Oct 26.
Autor:
Overbeek JK; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands. Electronic address: Joanneke.Overbeek@radboudumc.nl., Guchelaar NAD; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Mohmaed Ali MI; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Ottevanger PB; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., Bloemendal HJ; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., Koolen SLW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands; Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, South Holland, the Netherlands., Hamberg P; Department of Internal Medicine, Franciscus Gasthuis and Vlietland, Rotterdam, South Holland, the Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands; Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, Utrecht, the Netherlands., Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Opdam FL; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, North Holland, the Netherlands., Ter Heine R; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands., van Erp NP; Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, Gelderland, the Netherlands.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 194, pp. 113346. Date of Electronic Publication: 2023 Sep 19.
Autor:
Schutte T; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Medical Oncology, de Boelelaan, Amsterdam, The Netherlands., Zeverijn LJ; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., Geurts BS; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., de Wit GF; The Netherlands Cancer Institute, Division of Molecular Oncology and Immunology, CX Amsterdam, The Netherlands., Kok M; The Netherlands Cancer Institute, Department of Medical Oncology, CX Amsterdam, The Netherlands., Opdam FL; The Netherlands Cancer Institute, Department of Medical Oncology, CX Amsterdam, The Netherlands.
Publikováno v:
The oncologist [Oncologist] 2023 Jul 05; Vol. 28 (7), pp. e493-e497.